Fosun Pharma (600196.SH) announced on September 27th that its subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., had recently had its pharmaceutical registration application for SBK010 oral solution (hereinafter referred to as "the new drug") accepted by the National Medical Products Administration. The new drug is a chemical drug licensed to the group (i.e., the company and its holding subsidiaries/units, the same below) from Chengdu Seebio Biotech Technology Co., Ltd., intended for the treatment of mild to moderate acute ischemic stroke.
复星医药(600196.SH)：SBK010口服溶液获药品注册申请受理
Fosun Pharma (600196.SH): SBK010 oral solution has obtained acceptance of the pharmaceutical registration application.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated